替诺福韦酯治疗慢性乙型肝炎的最新进展

摘要

在众多核苷和核苷酸类药物（NAs）中，替诺福韦（TDF）以其强效、低耐药性及对多种 NAs治疗失败的慢性乙型肝炎（CHB）患者有效的特点脱颖而出，使其在临床HBV感染治疗中被广泛应用。介绍了TDF对CHB初治患者和经治患者的疗效，并分析了其对肝硬化患者治疗的效果，同时也对TDF治疗的安全性进行了评估。认为TDF耐药率低、安全性好，为目前CHB治疗的一线药物。%There are 400 million individuals infected with chronic hepatitis B virus (HBV)all over the world.The management of chronic hepatitis B (CHB)has been improved markedly over the last decade,primarily due to the availability of oral nucleoside analogue (NA) therapy.Among the numerous NAs,tenofovir disoproxil fumarate (TDF)stands out for its high therapeutic efficacy,low drug resistance, and wide disease spectrum against several types of chronic CHB that can not be cured with NAs.Thus,TDF has been widely used for clinical treatment of chronic HBV infection.This paper describes the efficacy of TDF in nave and treated patients and analyzes its effect on cirrho-sis.Furthermore,the safety of TDF therapy is assessed.It is considered that TDF has low resistance rate and high safety,which provides a first-line drug for CHB treatment.